Lakefront Biotherapeutics American Depositary Shares
LKFT
79 hedge funds and large institutions have $393M invested in Lakefront Biotherapeutics American Depositary Shares in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 25 reducing their positions, and 16 closing their positions.
1,050% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $1.34M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 25
7% less funds holding
Funds holding: 85 → 79 (-6)
9.52% less ownership
Funds ownership: 30.25% → 20.73% (-9.5%)
20% less capital invested
Capital invested by funds: $494M → $393M (-$101M)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$21.8M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$17.5M |
| 3 |
DCM
DME Capital Management
New York
|
+$6.66M |
| 4 |
Optiver Holding
Amsterdam,
Netherlands
|
+$1.67M |
| 5 |
CGH
Crossmark Global Holdings
Houston,
Texas
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$153M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.1M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$8.74M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.55M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.61M |
LKFT Hedge Fund Activity: Q3 2024 in Review
79 of the 6,980 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2024, worth a combined $393M — down 20% from $494M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LKFT and 10 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 25 added.
The largest buyer was Logos Global Management, opening a new position worth an estimated $21.8M. The largest seller was EcoR1 Capital, cutting an estimated $153M.
- 79 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2024, down from 85 in Q2 2024.
- Funds reported $393M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2024, down 20% quarter-over-quarter.
- 10 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2024 and 16 closed out, a net change of -6 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2024 was Logos Global Management, an estimated $21.8M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2024 was EcoR1 Capital, an estimated $153M sold.
Based on aggregated 13F filings for Q3 2024.